Compare IONQ & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IONQ | BBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9B | 15.9B |
| IPO Year | 2020 | 2019 |
| Metric | IONQ | BBIO |
|---|---|---|
| Price | $43.06 | $84.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 25 |
| Target Price | $66.69 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 18.5M | 2.0M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,235,000,000.00 | $502,076,000.00 |
| Revenue This Year | $84.91 | $89.45 |
| Revenue Next Year | $53.45 | $73.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $25.89 | $46.81 |
| 52 Week High | $84.64 | $93.42 |
| Indicator | IONQ | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 63.11 |
| Support Level | $38.88 | $78.90 |
| Resistance Level | $54.53 | $93.42 |
| Average True Range (ATR) | 2.60 | 2.70 |
| MACD | 1.60 | -0.18 |
| Stochastic Oscillator | 87.08 | 61.86 |
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.